NeurAxis (NRXS) Registration Filing summary

Company overview and business model

• Focuses on neuromodulation therapies for chronic and debilitating conditions in children and adults, leveraging proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology.

• Flagship product, IB-Stim, is FDA-cleared for functional abdominal pain associated with IBS in adolescents aged 11-18; additional pediatric clinical trials are ongoing.

• Incorporated in Indiana in 2012, rebranded and reincorporated in Delaware in 2022.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is $19,702,173.12, based on 7,176,393 shares at $3.13 per share as of January 27, 2024.

• Common stock is listed on NYSE American under the symbol "NRXS"; closing price was $2.60 on February 4, 2025.

Use of proceeds and capital allocation

• Net proceeds from company-offered securities will be used as set forth in the applicable prospectus supplement.

• No proceeds will be received from the sale of shares by selling stockholders; all such proceeds go directly to them.